David Rintell, Ed.D.
Dr. Rintell’s focus is on strengthening ties with patient advocacy organizations, and implementing the BridgeBio core value of Putting Patients First. He also is head of patient advocacy at QED Therapeutics and BridgeBio Pharma. Previously, Dr. Rintell was head of global patient advocacy for rare diseases at Sanofi Genzyme in Cambridge, Massachusetts. At Genzyme, he led an international team working with patient organizations in lysosomal storage disorders, genetic ocular diseases and ATTR Amyloidosis. Prior to working in the biotech industry, he held clinical appointments at two Harvard Medical School-affiliated hospitals, Massachusetts General Hospital and the Brigham and Women’s Hospital; as a clinical psychologist, he focused on assessing and treating patients with chronic diseases, with a specialization in multiple sclerosis in adults and children. He was also on the faculty of Brandeis University’s graduate program in genetic counselling, training future professionals who will help families understand genetic conditions. He served several patient advocacy organizations as a board member, member of clinical advisory committees and volunteer. His many publications focus on the psychosocial impact of medical illness and psychosocial adaptation to chronic medical illness. He is a clinical instructor in psychiatry at Harvard Medical School, and Professor of the Practice Emeritus at Brandeis University. He holds a Doctor of Education in Counseling Psychology from Boston University.